WO2016030357A1 - System for removing pro-inflammatory mediators as well as granulocytes and monocytes from blood - Google Patents
System for removing pro-inflammatory mediators as well as granulocytes and monocytes from blood Download PDFInfo
- Publication number
- WO2016030357A1 WO2016030357A1 PCT/EP2015/069415 EP2015069415W WO2016030357A1 WO 2016030357 A1 WO2016030357 A1 WO 2016030357A1 EP 2015069415 W EP2015069415 W EP 2015069415W WO 2016030357 A1 WO2016030357 A1 WO 2016030357A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- device
- filter
- membrane
- housing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration
- A61M1/3403—Regulation parameters
- A61M1/3406—Physical characteristics of the filtrate, e.g. urea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration
- A61M1/3403—Regulation parameters
- A61M1/341—Regulation parameters by measuring the filtrate rate, volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0014—Special media to be introduced, removed or treated removed from the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
- A61M2202/0441—Granulocytes, i.e. leucocytes containing many granules in their cytoplasm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
- A61M2202/0443—Macrophages, e.g. monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0445—Proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/20—Specific permeability or cut-off range
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis, ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
Abstract
Description
System for the removal of pro-inflammatory mediators as well as granulocytes and monocytes from blood
Description:
The present invention relates to a system for treating blood,
in particular for the treatment of sepsis.
Sepsis and systemic inflammatory responses (SIRS) are with mortality rates between 30-70%, the leading cause of death in intensive care units. Sepsis is a disease that is characterized by a complex systemic inflammatory reaction of the organism to the penetration of infectious agents. The inflammatory response leads to organ dysfunction varying degrees and often ends with the death of the patient.
Affected patients die not so much to the direct effects of bacterial infection, but above all to the systemic effects of the often excessive inflammatory response of the body. Control of these immune response in which the production of so-called pro-inflammatory mediators such as cytokines occupied by neutrophils and monocytes play a key role, is increasingly difficult to control with progression of sepsis.
In the standard treatment of sepsis, the administration of antibiotics and supportive measures, that need adapts the administration of circulatory support
Drugs, mechanical ventilation and renal replacement therapy established. The addition zytokinhemmender substances, however, has not proven to be effective. In recent years, moreover,
presented various concepts for the removal of cytokines, on the one hand by extracorporeal hemofiltration, on the other hand by extracorporeal adsorption.
Concepts for the removal of cytokines or generally proinflammatory mediators by extracorporeal hemofiltration, for example, in US-A 5,571,418, the US2012 / 0312732, EP-A 2281625, WO 03/009885 or WO 201 1 / 131,534th Extracorporeal adsorption of
Cytokines for example, is the subject of DE-A 199 13 707, WO
2013/025483, the WO2012 / 094565 or US 2013/001 1824th
Finally, methods and apparatus are described for their implementation in which cytokines through a membrane filter in the form of, for example, ultrafilters or
Plasma filters are removed with the permeate from the blood and in which subsequently passed, the permeate contained the cytokines through an adsorber for the specific adsorption of the cytokines, and finally the so purified permeate is returned to the patient (see, eg, WO 00/02603, WO03 / 009885, US2012 / 0312732, EP-A 0787500, EP-A 0958839).
Experiments on septic animal model reported here indicate a positive effect of Zytokinfiltration (in pigs) or Zytokinadsorption (in rats). First human studies could not confirm this but so far, although an effective reduction in cytokine levels could be detected in the blood.
Disadvantage of the pure Zytokinentfernung by extracorporeal method - whether by filtration or adsorption - is that inflammatory activated,
zytokingenerierende leukocytes are not thereby eliminated and their continuing excessive immune response and thus the disease process will continue talking. WO 2007/025735 is concerned with the treatment of sepsis and follows the approach that activated leukocytes contribute to the production of cytokines, which in turn activate other immune cells, which eventually leads to the systemic over-reaction of the immune system and sepsis. For the treatment of sepsis, WO 2007/025735 therefore proposes a filter for the removal of activated leukocytes, flows in the blood in the so-called dead-end mode through a filter material, are in the restrained, the leukocytes and thus removed from the blood. The filter material may be in a
Embodiment with ligands or other bioactive substances may be provided, for example, specifically interact with cytokines and an additional removal of cytokines to the flow of the to
cause blood treated by the filter material. The present invention aims to provide for its object a system for treating blood provided by means of which especially suffering from sepsis patients can be treated in an efficient manner.
The object is achieved by a blood processing system comprising
at least a first device and at least one second device,
wherein the blood side a first at least a first device
Flow path for passing the blood and the at least one second device having a second blood-side flow path for passing blood, and wherein the at least one first device and at least a second apparatus are connected in series so serially, that the first blood side flow path in fluid communication with the second blood-side flow path stands,
wherein the at least one first device is a membrane filter for the removal of toxic mediators from blood, and at least one second
Device for removal of granulocytes and monocytes is suitable from blood and wherein the membrane filter comprises a housing, a formed in the housing filter interior and disposed in the filter interior semipermeable membrane which divides the filter interior into a retentate space and a permeate space,
- the housing having a blood inlet means, and
having blood outlet communicating with the retentate in fluid communication, and the blood inlet means, the retentate and the
Blood outlet the first blood-side flow path for
forming passing blood through the first device and
- wherein the housing further comprises a permeate outlet for the discharge of light passing through the semi-permeable membrane permeate from the permeate area and
wherein the membrane filter having a release characteristic such that the sieving coefficient for albumin SK A ib in the range of 0.015 to 0.35.
In the application is carried out with the inventive blood treatment system, a cascade-like, that is sequential treatment of the system flowing through and to be treated the blood, are in located in the at least one first device proinflammatory mediators, such as cytokines, and in the second device granulocytes and monocytes. The blood can pass through the inventive system so that it first passes at least a first device through, and thus the pro-inflammatory mediators be removed first and then the at least one second device for the removal of granulocytes and
Monocytes. It is also possible that the blood so passed through the invented system is that it initially flows through the at least one second device, in which case so that first the granulocytes and monocytes are removed, and then the at least one first device for the removal of pro-inflammatory mediators. The at least one first and at least a second device are interconnected so that the first blood side flow path for
Passing blood of the first device in fluid communication with the second blood-side flow path of the second device is available. It follows that the gas introduced into the system blood as it passes through the at least one first and the at least one second device is treated in two separate steps in sequence. The processes of
Removal of proinflammatory mediators and the removal of
Granulocytes and monocytes are decoupled from each other and are given at the blood itself instead. Decoupling has the advantage that the individual
Devices can be specifically geared to the respective removal process.
Depending on the application, it is possible that the system for blood treatment comprising a single first device and a single second device, the blood-side flow paths are connected. However, it is also possible that, for example, a single first device having two mutually parallel second devices is connected so that the first
leaving the apparatus and with respect. proinflammatory mediators purified retentate on two divided streams, and the second blood-side
Flow paths of the two second devices is supplied. It is also possible that the system for blood treatment comprising a single first device and a single second device and the first device
leaving retentate is divided into two streams, wherein the one
Stream flows through said single second device and the second material flow is guided in the bypass without a further treatment. The second
leaving and apparatus related. granulocytes and monocytes purified material flow as well as guided in the bypass stream can then in
be seen the flow direction brought together behind the second device and are fed as total current, for example, the patient to be treated. Of course, other combinations of single or multiple first and second devices in the inventive system are for
Blood treatment possible.
In the membrane filter the blood to be treated flows in the first blood-side flow path through the blood inlet means into the filter interior and on the retentate side of the semipermeable membrane by the retentate. When the flow through the Retentatraums a portion of the treated blood acts as a permeate or ultrafiltrate through the semipermeable membrane, wherein the semipermeable membrane is adapted in terms of size of their pores, that to be removed from the blood proinflammatory mediators or as a part of the permeate . ultrafiltrate can be transported through the pores into the permeate. The treated and in terms of proinflammatory
Mediators depleted blood leaves on the first Strömungspad on the blood outlet of the membrane filter, while the permeate from the blood of the removed proinflammatory mediators containing the
exits membrane filter through the permeate.
In a preferred embodiment, the semi-permeable membrane
at least one hollow fiber membrane having a wall and a space enclosed by the wall lumens. The at least one hollow fiber membrane may comprise in a preferred embodiment, through its wall, an asymmetric pore structure with a release layer on the lumen side facing the wall of the hollow fiber membrane. Particularly preferred is a variety of
Hollow fiber membranes arranged in the membrane filter into a bundle. In a particularly preferred embodiment the retentate is the
Membrane filter formed from the lumen of at least one hollow fiber membrane.
The semipermeable membrane of the membrane filter is preferably a hydrophilic membrane. The hydrophilic membrane of a hydrophobic first polymer in a particularly preferred embodiment is constructed, which is combined with a hydrophilic second polymer. As the hydrophobic first polymers engineering plastics come from the group of aromatic sulfone, such as polysulfone, polyethersulfone, polyphenylenesulfone or polyarylethersulfone, polycarbonates, polyimides, polyetherimides,
Polyether ketones, polyphenylene sulfides, copolymers or modifications of these polymers, or mixtures of these polymers. In a particularly preferred embodiment, the hydrophobic first polymer is a polysulfone or a polyether sulfone in the following formulas (I) and (II) shown recurring molecular units
The hydrophilic second polymer advantageously long-chain polymers are used which have, on the one hand, a compatibility with the synthetic first polymer, and which have repeating polymer units which are hydrophilic per se. Preferably, the hydrophilic second polymer is polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, Polyglykolmonoester, Polysorbitat, such as polyoxyethylene sorbitan monooleate, carboxymethyl cellulose or a modification or a copolymer of these polymers. Particularly preferred is polyvinylpyrrolidone.
The membrane filter for the removal of pro-inflammatory mediators, for example, the shape of conventional hemofilter have, in which the supply and discharge of the treated blood via a blood inlet means and a blood outlet takes place in the end caps of the membrane filter, with the forming the retentate lumens arranged the bündeiförmig in the membrane filter hollow fiber membranes are in fluid communication. In the
The space enclosing the hollow-fiber membranes, that is in the permeate or filtrate chamber, flows generally over the wall of the housing at least one
Outlet means, ie the permeate, on the permeate, which contains the removed from the blood pro-inflammatory mediators, the
Membrane filter leaves. However, with regard to the contained semi-permeable membrane, the membrane filter of the invention differs from the usual Hemofiltern, as explained below.
In the at least one first device, ie in the membrane filter for the removal of toxic mediators from blood in the application of the flowing on the retentate blood a portion of plasma water is removed as ultrafiltrate, wherein the ultrafiltrate contains the toxic mediators contained in the blood, due to their molecular size in the so-called middle molecular region due to the separation characteristics of the membrane through the semipermeable
can contact membrane. Essential components of the blood as the cellular components, larger dissolved in the blood plasma proteins such as albumin, immunoglobulins, HDL or LDL, antibody or Fribrinogene other hand, are retained for the most part or almost completely by the membrane filter contained in the semipermeable membrane. Of this semipermeable membrane containing membrane filter according to the invention according to the invention has a sieving coefficient for albumin in blood SK A ib in the range of 0.015 to 0.35. Preferably, the filter membrane, the sieving coefficient for albumin in blood SK A ib in the range of 0.05 to 0.3 and particularly preferably in the range of 0.1 to 0.25. thus the semipermeable membrane of the membrane filter according to the invention allows albumin to remove toxic mediators may be partly linked to the to certain shares by. Membrane filter according to the invention with such a sieving coefficient have a separation limit in the range of 50,000 to 150,000 Dalton.
In a further preferred embodiment, the membrane filter or through the semipermeable membrane of the membrane filter immunoglobulin G (IgG) with a molecular weight of about 180,000 daltons almost completely
retained. Preferably, the membrane filter has a sieving coefficient for IgG SkiGo in the range of 0.001 to 0.1. More preferably, the
Sieving coefficient for IgG SKi gG in the range of 0.003 to 0.08.
thus the semipermeable membrane contained in the novel membrane filter or membrane filter according to the invention differs from the
Region of the blood plasma cleaning filters used in many cases, a
have cut point above approximately two million Dalton and which via a separation of blood plasma almost complete separation of the above, dissolved in the blood plasma components of the blood cells. Thus, the plasma membranes contained in such plasma filters have a much more open structure than the membranes of the invention
Membrane filter. This open structure affects simultaneously in high
Permeability of plasma membranes from, resulting in
Ultrafiltration rates for water, U FRwasser, of above about 15,000 ml / (hm 2 mmHg).
On the other side of the membrane filter according to the invention, or the semi-permeable membrane of distinguishes Hemodialysatoren contained therein,
Hemodiafiltern or Hemofiltern or the membranes used therein, the separation limit is up to about 40,000 daltons formed in whole blood, to albumin and molecules larger than albumin at least substantially retain, and in which the sieving coefficient for albumin in blood SK A ib of less than 0.005 will be realized. Preferably, the semipermeable membrane of the present membrane filter having an ultrafiltration rate in water or hydraulic permeability U FRwasser in the range of 500 to 2000 ml / (hm 2 mmHg). Particularly preferably, the hydraulic permeability is in the range of 500 to 1500 ml / (hm 2 mmHg). Best suitable is a semipermeable membrane with a U FRwasser in the range of 800 to 1200 ml / (hm 2 mmHg). This ensures a sufficiently rapid
Removal of toxic mediators during the blood treatment achieved ..
In the application, the permeate generated in the membrane filter or ultrafiltrate containing the removed from the blood proinflammatory mediators are discarded. However, it is also possible to purify the permeate or ultrafiltrate, that is, for example, to remove the pro-inflammatory mediators from the permeate by means of suitable adsorbers, and to return the purified permeate the treated blood stream.
The second device, which is designed for the removal of granulocytes and monocytes and are suitable, for example Centrifugal devices can be used. Preferably, however, the at least one second device for the removal of granulocytes and monocytes to a filter to have an adsorber or a combination of both which are designed for the removal of granulocytes and monocytes and suitable.
In a preferred embodiment, the at least one second
Device may be a filter for the removal of granulocytes and monocytes with a filter housing having an interior space and an inlet means and an outlet communicating with the interior space in fluid communication,
- wherein in the interior of the filter housing exhibiting a flow channel and flowed through filter material is arranged in these flow channels of blood, - said inlet means, outlet means and the flow channels of the filter material in the interior forming the second flow path, and
- wherein the filter material is adapted for the separation of granulocytes and monocytes by size-exclusion and / or by adsorption.
The filter material may be a fibrous material, for example a fleece-like material or a material in the form of one or more fabric layers. Such filters are for example in EP-A 0155003, EP-A 1444996, EP-A 1 553 1 13, EP-A 1,582,228, the
EP-A 1754496, US 201 1/0031 191, WO 2004/018078, WO
2004/039474, WO 2005/002647 or WO 2006/061862. In the disclosed in these documents, filters can in the set
Filter materials in addition to or instead of a distance of granulocytes and monocytes via size exclusion and removal of specific interactions between the filter material and the granulocytes and
, Ie for monocytes by adsorption. There are also filter with filter materials are known, are adapted to their surface properties for the adsorption of leukocytes, granulocytes or monocytes (see for example EP-A 0478914, EP-A 0606646, EP-A 1 01 6 426, US-A 4 476023, WO 2004/064980, WO 2008/028807). Such filters for removing leukocytes, granulocytes and monocytes are also under the trade name Cellsorba ™ (from. Asahi Medical Co. Ltd.) are commercially available.
The filter material may also be in the form of porous materials to be removed from blood from which leukocytes example, can flow through. Porous filter materials in the form of semi-permeable membranes are disclosed for example in EP-A 0606646, EP-A 1666129 or US-A 5,478,470. In a further preferred embodiment of the system for treatment of blood, the at least one second device may be an adsorber comprising a housing for the removal of granulocytes and monocytes from blood comprising an enclosing an inner space inside, and a
having inlet means and outlet means,
- wherein in the interior of a plurality of filaments is arranged,
- the yarns with at least one of its ends so in one with the
Housing inner side connected potting compound are embedded that the threads around a through-flow of blood outside space is formed, which communicates with the inlet means and the outlet means in fluid communication, whereby inlet means, outlet means and interior forming the second flow path,
- wherein the arrangement of the filaments has a high degree of order, it being understood under a high degree of order that a proportion of at least 25% of the filaments along their extension direction are arranged side by side and
- wherein the fibers based on organic polymers, a formation of the
Cause complement activation product C5a in a concentration of at least 10 micrograms per m 2 of fiber surface.
Preferably it is in the threads in these devices
Hollow fibers with a lumen and a lumen enclosing wall as well as with an inner luminal surface and an outer surface, wherein the hollow fibers are arranged in the housing so that only the outer surfaces of the hollow filaments for the exterior space by flowing blood accessible, the lumens of the hollow fibers however, are not accessible for a fluid.
Such adsorber for removing leukocytes, such as granulocytes and monocytes, are described in US 2008/0203024 and US 2010/0084331
described, it is expressly referred to the disclosure here. In a further preferred embodiment, the at least one second device for the removal of granulocytes and monocytes from blood, a
be adsorber comprising a housing having an inner space enclosing an inner side and an inlet means and an outlet means, wherein in the interior of a built particulate adsorbent material is arranged. Around the particles of the adsorbent material around a through-flow of blood outside space is formed, which communicates with the inlet means and the outlet means in fluid communication, whereby inlet means,
Outlet means and interior forming the second flow path. The blood flows in these adsorbents in the application on the second blood-side flow path via the inlet arrangement into the interior, flows around the adsorbent and leaves the interior via the outlet.
Preferably, in the adsorbers as adsorbent particles based on Celluloseacatat or styrene may be used. However, other materials such as polyamides, polyethylene terephthalate or polyacrylonitrile are known which have been subjected to a surface modification or are provided with a coating. Such adsorber as a second device for the removal of
Granulocytes and monocytes are suitable, also the subject of various patent publications (see for example EP-A 0319961, EP-A 1882738, WO 2000/55621, US-A 4370381) and are available as commercial products, for example, under the trade designation Adacolumn ® (Messrs. JIMRO Co., Ld.) available.
In a preferred embodiment of the system for treatment of blood, the at least one first device for the removal of pro-inflammatory mediators, a membrane filter and the at least one second device for the removal of granulocytes and monocytes is an adsorber comprising a housing, in whose interior a plurality of filaments having a high degree are arranged in order, as previously described. Particularly preferably, in the membrane filter to such, wherein the at least one semipermeable membrane is a semipermeable hollow fiber membrane. In this preferred embodiment, with a membrane filter and an adsorber based on arranged in a high degree of order strands as first and second device, the two devices are interconnected so that the retentate of the first device with which the threads of the second
Apparatus surrounding outer space in fluid communication. In the particularly preferred embodiment, with a membrane filter with the lumens of hollow fiber membranes are of the semipermeable hollow fibers that constitute the retentate with which the threads of the second device surrounding outer space in fluid communication.
In use, the blood to be treated on the first blood-side flow path through the blood inlet arrangement of the membrane filter in the retentate of the membrane filter flows for these embodiments, flows through the latter, with pass through filtration, a part of the treated blood as permeate through the semipermeable membrane and wherein at the filtration takes place a distance of proinflammatory mediators. After passing through the
Retentatraums the retentate leaving the membrane filter on the
While the removed blood outlet from the blood
proinflammatory mediators containing ultrafiltrate via the retentate is removed from the membrane filter. The retentate, ie the first in the
Apparatus treated blood, flows to the second blood-side flow path via the inlet arrangement of the adsorber into the outer space around the threads disposed in the adsorber after leaving the membrane filter and flows over the threads on its outer side. In this case, a distance of granulocytes and monocytes is performed from the overflowing thread and the blood to be treated. Via adsorption to the filaments Which is then treated in the second device and now of pro-inflammatory mediators as well as granulocytes and monocytes purified blood then exits the adsorber via its outlet. It is also possible that the blood to be treated until the first device and then flows through the second device. For the above preferred
Embodiments, this means that then the application's to
treated blood in the second blood-side flow path through the
Inlet means of the adsorber into the outer space around the one- arranged in the adsorber threads and flows over the threads on its outer side. In this case, a distance of granulocytes and monocytes is performed from the overflowing thread and the blood to be treated. Via adsorption to the filaments The blood treated in the second device and purified from granulocytes and monocytes then leaves the adsorber via its outlet.
This treated in the second device, blood flows after leaving the adsorber on the first blood-side flow path through the
Blood inlet arrangement of the membrane filter into the retentate of
Membrane filter, flows through this, wherein a portion of the blood to be treated passes and filtration as permeate through the semipermeable membrane takes place a distance of proinflammatory mediators during filtration. After flowing through the Retentatraums the retentate leaves, that is, the blood treated in the first device and now of
proinflammatory mediators and purified from granulocytes and monocytes blood the membrane filter through the blood outlet. The permeate the pro-inflammatory mediators is containing the
Permeate removed from the membrane filter.
proinflammatory at least one first removal apparatus
Mediators and at least one second device for the removal of
Granulocytes and monocytes can be connected in series as separate devices of the system according to the invention, wherein, as stated above, the order of the devices and the order in which the blood to be treated passes through the devices which can be adapted to the requirements of the blood treatment. However, it must
Devices to be connected together so that the first blood side
A flow path of the first device and the second blood-side flow path are provided at least the at least one second device to each other in fluid communication and the two blood-side flow paths
are flowed through in succession by the treated blood, that flows through in the application in the blood treatment sequentially. The first device and second device may for example via suitable
Hose connections, connection fittings or adapters be interconnected. First and second device may also have the shape of cylinders, for example, directly through an adhesive, welding, screwing or
Flange are interconnected. Here, the first device may be a hollow fiber membrane module in which the hollow fiber membranes arranged in a cylindrical housing substantially parallel to each other in the direction of the longitudinal axis of the cylindrical housing and the lumens of the
Hollow fiber membranes are flow against the housing ends. The second device also having a cylindrical housing, for example, may include an array of threads for the adsorption of granulocytes and monocytes, a fibrous filter material or a particulate adsorbent material can then be flanged at one end of the housing to one of the housing ends of the first device, or with a the housing ends of the first device, for example, glued welded or screwed by means of a union nut. Other integral types of the system for blood treatment are possible. The second device can be configured as an end cap, comprising a column filled with an adsorbent chamber and which is screwed onto one end of a cylindrically shaped first device. Also, the system for treating blood can be so formed that the second
Device is concentrically arranged in the form of a jacket around the housing of a first device having a cylindrical shape and so first and second means form an integral unit.
The determination of the parameters for the characterization of the semipermeable membrane of the membrane filter of the first apparatus, the following
Measurement methods to basically set:
Determination of sieving coefficient for the membrane filter:
The Siebkoefizienten SK are for c acid glycoprotein (M w = 44,000 Daltons), SK Gp, albumin (Mw = 68,000 Daltons), SK A |b, and for immunoglobulin G (M w = 180,000 daltons), SKi gG determined. The determination of sieving coefficients is according to DIN EN ISO 8637: 2014-03, particularly Section 5.6.2 and Figure 5, with freshly donated human heparinized blood (10 IU / ml) was performed on a dialysis machine (Nikkiso DBB 03), wherein the whole blood during the measurement is being driven recirculating. The blood is before the experiment to a
Hematocrit of 32% and a total protein concentration of 60 g / L adjusted. The determination of the hematocrit is carried out with a cell counter (for example, ABC Pentra 60 Axon Lab AG) and the determination of total protein concentration using a clinical analyzer (Cobas example c 1 1 1, Roche Diagnostics).
The membrane filter is washed first with 1 liter of saline in single-pass and
then with a further liter recirculating Saline (20 min, 200 ml / min) rinsed. In the second rinsing step (MPC, Ismatec) rinsing liquid via the membrane filter into the filtrate is drawn off by means of an external pump (min 60 ml /). The saline is then completely displaced by the blood and B = 300 ml / min and a filtrate flow Q F = started the experiment at 37 ° C with blood flow Q 60 ml / min (= 20% of the blood flow). Samples from Blutein- and after 60 min - output and a filtrate sample taken, obtained therefrom by centrifuging the plasma and the levels of ai acid glycoprotein, albumin, and IgG determined by laser nephelometry (BN ProSpec, Siemens Diagnostics). The Siebkoeffizientenberechnung as indicated in section 5.6.2.4 of DIN EN ISO
8637: 2014-03 described.
Trennqrenze:
To determine the cut point are determined in accordance with the method described above for sieving coefficients ai acid glycoprotein (Mw = 44,000 daltons), SK Gp, albumin (Mw = 68,000 daltons), SK A |b, and for immunoglobulin G (M w = 180,000 daltons), SKi gG plotted in a diagram of the molecular weight. Including assumed vertices at 10,000 Daltons with a sieving coefficient SK = 1 and at 1 million Dalton with a
Sieving coefficients SC = 0 is placed a smooth curve through the points. As the molecular weight cutoff is detected at a retention of 95% or, with a sieving coefficient of 0.05 SK.
Hollow fiber membranes:
To determine the hydraulic permeability and of ultrafiltration rate UFR in water Wa ter contained in the membrane filter semipermeable membrane a test cell with a defined number and length hollow fiber is made using the hollow fiber membranes to be tested. The hollow fibers are embedded for both sides at their ends in hot wax. After hardening of the wax, the embeddings are cut free so that the lumens of the
Hollow fiber membranes are opened by the cut. The hollow fiber lumens in the embeddings must be checked for consistency. The length of the test cell is usually from 300 +/- 5 mm. The number of
Hollow fiber membranes is usually between 1 60 - 240. The effective area of a test cell is defined as follows:
WithA = effective area [m 2]
n = number of capillaries
I = free length of the capillaries [mm]
di = inside diameter of the capillaries [μηι]
FDIM = dimension of factor [1 - 1 0 "9 m 2 / (mm ^ m)]
The test cell is in front of the measurement for at least 1 5 minutes
Room temperature in deionised water stored (wetting) and then incorporated into a test apparatus. The measurement is carried out at 37 ° C tempered ultrafiltered and deionized water. The test cell is fully immersed in water heated during the measurement. The test pressure before the test cell is set to 200 ± 2 mbar. When measuring it is a dead-end method. The test cell is first conditioned for 900 s under test pressure. The actual measuring time following is 60 s, in which the permeate produced during the measurement is detected volumetrically.
The U FRwasser is determined according to the following formula:
V w
U FRwasser = [ml / (hm 2 mmHg)]
Δΐ Po + PE
■ ■ A () ■ f, orr
3600 2
Where:
V w = sample through the membrane during the measurement time streamed
Water volume [ml]
Δΐ = measuring time [s]
A = effective area [m 2] Test pressure [mbar] (pressure upstream of the test cell)
Discharge pressure [mbar] (pressure after the test cell)
1/1, 33322; Conversion [mbar] to [mmHg] flat membranes:
Disc-shaped membrane samples are punched with a diameter of 15 cm out of the tested flat membrane and a fluid-tight so clamped into a suitable sample holder on the circumference, that a free measuring area of 43.20 cm 2 results. The sample holder is located in a housing which can be flowed through by pressurized water. The clamped membrane sample is then allowed to swell in first at 37 ° C temperature-controlled, deionized water, and then flows through to 37 ° C temperature-controlled, deionized water under a defined pressure between 0.4 and 1, 0 bar. After an interval of 50 s until constant If the pressure which is determined flowed during a measuring time of 60 seconds through the membrane sample through volume of water gravimetrically or volumetrically.
The ultrafiltration rate UFR Wa ter is according to the formula V w
U FRwasser = 800 ■ - [ml / (hm 2 mmHg)]
Δΐ-Α-ρο determined. Where:
V w = sample through the membrane during the measurement time having passed water volume [ml]
At = measurement time [min]
A = flow-through area of the membrane sample (43.20 cm 2)
Po = the pressure set during the measurement [bar]
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14182261.9 | 2014-08-26 | ||
EP14182261 | 2014-08-26 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017510850A JP2017525489A (en) | 2014-08-26 | 2015-08-25 | System for removing from the blood inflammatory mediators as well as granulocytes and monocytes |
US15/505,724 US20170266362A1 (en) | 2014-08-26 | 2015-08-25 | System for removal of pro-inflammatory mediators as well as granulocytes and monocytes from blood |
EP15763840.4A EP3185926B1 (en) | 2014-08-26 | 2015-08-25 | System for the removal of pro-inflammatory mediators and granulocytes and monocytes from blood |
CN201580045367A CN106659834A (en) | 2014-08-26 | 2015-08-25 | System for removing pro-inflammatory mediators as well as granulocytes and monocytes from blood |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016030357A1 true WO2016030357A1 (en) | 2016-03-03 |
Family
ID=51392162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/069415 WO2016030357A1 (en) | 2014-08-26 | 2015-08-25 | System for removing pro-inflammatory mediators as well as granulocytes and monocytes from blood |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170266362A1 (en) |
EP (1) | EP3185926B1 (en) |
JP (1) | JP2017525489A (en) |
CN (1) | CN106659834A (en) |
WO (1) | WO2016030357A1 (en) |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4370381A (en) | 1980-03-12 | 1983-01-25 | Asahi Kasei Kogyo Kabushiki Kaisha | Granulocyte-separating material and granulocyte separator |
EP0155003A2 (en) | 1984-03-15 | 1985-09-18 | ASAHI MEDICAL Co., Ltd. | Filtering unit for removing leukocytes |
EP0319961A2 (en) | 1987-12-10 | 1989-06-14 | Japan Immuno Research Laboratories Co., Ltd. | Removal method of granulocytes from blood and granulocyte removing apparatus therefor |
EP0478914A1 (en) | 1990-07-27 | 1992-04-08 | Pall Corporation | Leucocyte depleting filter device and method of use |
EP0606646A1 (en) | 1992-12-28 | 1994-07-20 | Asahi Medical Co., Ltd. | Filtermaterial, apparatus and method for removing leukocytes |
US5478470A (en) | 1991-08-22 | 1995-12-26 | Asahi Medical Co., Ltd. | Filter material for selectively removing leukocytes |
US5571418A (en) | 1993-08-20 | 1996-11-05 | Lee; Patrice A. | Hemofiltration of toxic mediator-related disease |
EP0787500A1 (en) | 1996-02-06 | 1997-08-06 | BELLCO S.p.A. | Method and device for extracorporeal removal of toxins, in particular cytokines |
WO2000002603A2 (en) | 1998-07-10 | 2000-01-20 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
EP1016426A1 (en) | 1997-08-28 | 2000-07-05 | ASAHI MEDICAL Co., Ltd. | Leukocyte-removing filter material |
WO2000055621A2 (en) | 1999-03-17 | 2000-09-21 | Japan Immunoresearch Laboratories Co., Ltd. | Blood leucocyte apheresis for treatment of disease |
DE19913707A1 (en) | 1999-03-26 | 2000-10-05 | Privates Inst Bioserv Gmbh | Immunoadsorber to sepsis therapy |
WO2003009885A2 (en) | 2001-07-25 | 2003-02-06 | Immunocept, L.L.C. | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
WO2004018078A1 (en) | 2002-08-21 | 2004-03-04 | Fresenius Hemocare Italia S.R.L. | Filter for the depletion of leukocytes from blood products |
WO2004039474A2 (en) | 2002-10-25 | 2004-05-13 | Pall Corporation | Biological fluid filter |
WO2004064980A1 (en) | 2003-01-24 | 2004-08-05 | Fresenius Hemocare Italia S.R.L. | Filter for the separation of leukocytes from whole blood or blood preparations, method for production of said filter, corresponding device and use thereof |
EP1444996A1 (en) | 2001-10-16 | 2004-08-11 | ASAHI MEDICAL Co., Ltd. | METHOD OF SELECTIVELY ELIMINATING VIRUS AND LEUKOCYTES, ELIMINATING MATERIAL AND ELIMINATING APPARATUS |
WO2005002647A1 (en) | 2003-07-03 | 2005-01-13 | Fresenius Hemocare Italia S.R.L. | A filter for the removal of substances from blood products |
EP1553113A1 (en) | 2002-06-17 | 2005-07-13 | ASAHI MEDICAL Co., Ltd. | Biocompatible polymer and filter for selectively eliminating leucocytes using the same |
EP1582228A1 (en) | 2002-12-02 | 2005-10-05 | Asahi Kasei Medical Co., Ltd. | Method of removing leukocytes, leukocyte-removing filter and utilization thereof |
EP1666129A1 (en) | 2003-08-07 | 2006-06-07 | Asahi Kasei Kabushiki Kaisha | Composite porous membrane and process for producing the same |
WO2006061862A1 (en) | 2004-12-10 | 2006-06-15 | Fresenius Hemocare Italia S.R.L. | A porous web, particularly for filtration of biological fluids |
EP1754496A1 (en) | 2004-06-09 | 2007-02-21 | Asahi Kasei Medical Co., Ltd. | Method for removing leukocyte and filter for use therein |
WO2007025735A1 (en) | 2005-08-31 | 2007-03-08 | Gambro Lundia Ab | Method and apparatus for the removal of immune cells |
EP1882738A1 (en) | 2005-05-20 | 2008-01-30 | Arkray, Inc. | Methods for recovering microorganism and nucleic acid using fine particle and kit to be used for the methods |
WO2008028807A1 (en) | 2006-09-06 | 2008-03-13 | Fresenius Hemocare Italia S.R.L. | A filter for the removal of substances from blood products |
WO2008083965A2 (en) * | 2007-01-13 | 2008-07-17 | Membrana Gmbh | Device for removing leukocytes from blood |
US20080203024A1 (en) | 2005-09-09 | 2008-08-28 | Horst-Dieter Lemke | Method for the Elimination of Leukocytes from Blood |
DE20321776U1 (en) * | 2002-12-20 | 2010-02-18 | Gambro Lundia Ab | Hollow fiber membrane for removing toxic mediators from blood |
US20110031191A1 (en) | 2008-04-14 | 2011-02-10 | Asahi Kasei Medical Co., Ltd. | Filter material for removing aggregates and method of filtering blood product |
WO2011131534A1 (en) | 2010-04-20 | 2011-10-27 | Gambro Lundia Ab | High cut-off hemodialysis membrane for use in liver dialysis |
WO2012094565A1 (en) | 2011-01-06 | 2012-07-12 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
US20120312732A1 (en) | 2007-01-12 | 2012-12-13 | Bellco S.R.L. | Use of Polymeric Resins for the Adsorptive Extracorporeal Removal of Inflammatory Mediators in the Treatment of Systemic Inflammation-Related Diseases |
WO2013025483A2 (en) | 2011-08-12 | 2013-02-21 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
US20130161247A1 (en) * | 2011-12-21 | 2013-06-27 | Infomed Sa | Apparatus for Blood Purification by Extracorporeal Circulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1776582A1 (en) * | 2004-07-30 | 2007-04-25 | Hans-Werner Heinrich | Device and method for isolating cells, bioparticles and/or molecules from liquids for use with animals, in biotechnology, (including biotechnological research) and medical diagnostics |
-
2015
- 2015-08-25 WO PCT/EP2015/069415 patent/WO2016030357A1/en active Application Filing
- 2015-08-25 JP JP2017510850A patent/JP2017525489A/en active Pending
- 2015-08-25 CN CN201580045367A patent/CN106659834A/en active Search and Examination
- 2015-08-25 US US15/505,724 patent/US20170266362A1/en active Pending
- 2015-08-25 EP EP15763840.4A patent/EP3185926B1/en active Active
Patent Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476023A (en) | 1980-03-12 | 1984-10-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Granulocyte-separating material and granulocyte separator |
US4370381A (en) | 1980-03-12 | 1983-01-25 | Asahi Kasei Kogyo Kabushiki Kaisha | Granulocyte-separating material and granulocyte separator |
EP0155003A2 (en) | 1984-03-15 | 1985-09-18 | ASAHI MEDICAL Co., Ltd. | Filtering unit for removing leukocytes |
EP0319961A2 (en) | 1987-12-10 | 1989-06-14 | Japan Immuno Research Laboratories Co., Ltd. | Removal method of granulocytes from blood and granulocyte removing apparatus therefor |
EP0478914A1 (en) | 1990-07-27 | 1992-04-08 | Pall Corporation | Leucocyte depleting filter device and method of use |
US5478470A (en) | 1991-08-22 | 1995-12-26 | Asahi Medical Co., Ltd. | Filter material for selectively removing leukocytes |
EP0606646A1 (en) | 1992-12-28 | 1994-07-20 | Asahi Medical Co., Ltd. | Filtermaterial, apparatus and method for removing leukocytes |
US5571418A (en) | 1993-08-20 | 1996-11-05 | Lee; Patrice A. | Hemofiltration of toxic mediator-related disease |
EP0958839A2 (en) | 1996-02-06 | 1999-11-24 | BELLCO S.p.A. | Method for extracorporeal removal of toxins, in particular cytokines, particularly for treating patients affected with acute organ failure |
EP0787500A1 (en) | 1996-02-06 | 1997-08-06 | BELLCO S.p.A. | Method and device for extracorporeal removal of toxins, in particular cytokines |
EP1016426A1 (en) | 1997-08-28 | 2000-07-05 | ASAHI MEDICAL Co., Ltd. | Leukocyte-removing filter material |
WO2000002603A2 (en) | 1998-07-10 | 2000-01-20 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
WO2000055621A2 (en) | 1999-03-17 | 2000-09-21 | Japan Immunoresearch Laboratories Co., Ltd. | Blood leucocyte apheresis for treatment of disease |
DE19913707A1 (en) | 1999-03-26 | 2000-10-05 | Privates Inst Bioserv Gmbh | Immunoadsorber to sepsis therapy |
WO2003009885A2 (en) | 2001-07-25 | 2003-02-06 | Immunocept, L.L.C. | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
EP1444996A1 (en) | 2001-10-16 | 2004-08-11 | ASAHI MEDICAL Co., Ltd. | METHOD OF SELECTIVELY ELIMINATING VIRUS AND LEUKOCYTES, ELIMINATING MATERIAL AND ELIMINATING APPARATUS |
EP1553113A1 (en) | 2002-06-17 | 2005-07-13 | ASAHI MEDICAL Co., Ltd. | Biocompatible polymer and filter for selectively eliminating leucocytes using the same |
WO2004018078A1 (en) | 2002-08-21 | 2004-03-04 | Fresenius Hemocare Italia S.R.L. | Filter for the depletion of leukocytes from blood products |
WO2004039474A2 (en) | 2002-10-25 | 2004-05-13 | Pall Corporation | Biological fluid filter |
EP1582228A1 (en) | 2002-12-02 | 2005-10-05 | Asahi Kasei Medical Co., Ltd. | Method of removing leukocytes, leukocyte-removing filter and utilization thereof |
EP2281625A1 (en) | 2002-12-20 | 2011-02-09 | Gambro Lundia AB | Perm selective asymmetric hollow fiber membrane for the treatment of sepsis |
DE20321776U1 (en) * | 2002-12-20 | 2010-02-18 | Gambro Lundia Ab | Hollow fiber membrane for removing toxic mediators from blood |
WO2004064980A1 (en) | 2003-01-24 | 2004-08-05 | Fresenius Hemocare Italia S.R.L. | Filter for the separation of leukocytes from whole blood or blood preparations, method for production of said filter, corresponding device and use thereof |
WO2005002647A1 (en) | 2003-07-03 | 2005-01-13 | Fresenius Hemocare Italia S.R.L. | A filter for the removal of substances from blood products |
EP1666129A1 (en) | 2003-08-07 | 2006-06-07 | Asahi Kasei Kabushiki Kaisha | Composite porous membrane and process for producing the same |
EP1754496A1 (en) | 2004-06-09 | 2007-02-21 | Asahi Kasei Medical Co., Ltd. | Method for removing leukocyte and filter for use therein |
WO2006061862A1 (en) | 2004-12-10 | 2006-06-15 | Fresenius Hemocare Italia S.R.L. | A porous web, particularly for filtration of biological fluids |
EP1882738A1 (en) | 2005-05-20 | 2008-01-30 | Arkray, Inc. | Methods for recovering microorganism and nucleic acid using fine particle and kit to be used for the methods |
WO2007025735A1 (en) | 2005-08-31 | 2007-03-08 | Gambro Lundia Ab | Method and apparatus for the removal of immune cells |
US20080203024A1 (en) | 2005-09-09 | 2008-08-28 | Horst-Dieter Lemke | Method for the Elimination of Leukocytes from Blood |
WO2008028807A1 (en) | 2006-09-06 | 2008-03-13 | Fresenius Hemocare Italia S.R.L. | A filter for the removal of substances from blood products |
US20120312732A1 (en) | 2007-01-12 | 2012-12-13 | Bellco S.R.L. | Use of Polymeric Resins for the Adsorptive Extracorporeal Removal of Inflammatory Mediators in the Treatment of Systemic Inflammation-Related Diseases |
US20100084331A1 (en) | 2007-01-13 | 2010-04-08 | Frank Heuser | Device for removing leukocytes from blood |
WO2008083965A2 (en) * | 2007-01-13 | 2008-07-17 | Membrana Gmbh | Device for removing leukocytes from blood |
US20110031191A1 (en) | 2008-04-14 | 2011-02-10 | Asahi Kasei Medical Co., Ltd. | Filter material for removing aggregates and method of filtering blood product |
WO2011131534A1 (en) | 2010-04-20 | 2011-10-27 | Gambro Lundia Ab | High cut-off hemodialysis membrane for use in liver dialysis |
WO2012094565A1 (en) | 2011-01-06 | 2012-07-12 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
US20130011824A1 (en) | 2011-01-06 | 2013-01-10 | Cytosorbents Corporation | Polymeric Sorbent for Removal of Impurities From Whole Blood and Blood Products |
WO2013025483A2 (en) | 2011-08-12 | 2013-02-21 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
US20130161247A1 (en) * | 2011-12-21 | 2013-06-27 | Infomed Sa | Apparatus for Blood Purification by Extracorporeal Circulation |
Also Published As
Publication number | Publication date |
---|---|
CN106659834A (en) | 2017-05-10 |
EP3185926A1 (en) | 2017-07-05 |
JP2017525489A (en) | 2017-09-07 |
US20170266362A1 (en) | 2017-09-21 |
EP3185926B1 (en) | 2018-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20010041892A1 (en) | Hemofiltration system including ultrafiltrate purification and re-infusion system | |
EP0305787A1 (en) | A process for manufacturing permselective asymmetric membranes suitable for haemodialysis and the so prepared membranes | |
US6866783B2 (en) | Module with membrane elements in cross-flow and in a dead-end arrangement | |
US4708799A (en) | Hollow fiber membrane for plasma separation | |
US5858238A (en) | Salvage of autologous blood via selective membrane/sorption technologies | |
EP2113298A1 (en) | Hollow fibre membrane with improved permeability and selectivity | |
WO2001024849A1 (en) | Membrane module for the hemodiafiltration with integrated pre- or postdilution of the blood | |
US20090112146A1 (en) | Kit, system and method of treating myeloma patients | |
US20060108288A1 (en) | Plasma purification membrane and plasma purification system | |
WO2013103906A1 (en) | Multi-staged filtration system for blood fluid removal | |
US5069788A (en) | Multi-pass blood washing and plasma removal device and method | |
JP2001170171A (en) | Semipermeable membrane for blood processing and dialyzer for blood processing using the same | |
JP2001170167A (en) | Method of manufacturing dialyzer and method of sterilization | |
US20020190000A1 (en) | Haemofiltration system | |
Hoenich et al. | Dialysers | |
WO2013012024A1 (en) | Porous hollow fiber membrane | |
US20080237127A1 (en) | Polysulfone Hemodialyzer | |
EP0750936A1 (en) | Permselective membranes and methods for their production | |
JP2007215569A (en) | Plasma component separator and blood purifying apparatus by double filtration | |
JPH10244000A (en) | Hollow fiber membrane type body fluid purification device and its production | |
JP2013071100A (en) | Porous hollow fiber membrane for protein-containing liquid treatment | |
JP2008237893A (en) | Blood treatment column | |
EP2253367A1 (en) | Membranes having improved performance | |
JP2001170172A (en) | Dialyzer for blood processing | |
JPH10180058A (en) | Hollow fiber membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15763840 Country of ref document: EP Kind code of ref document: A1 |
|
REEP |
Ref document number: 2015763840 Country of ref document: EP |
||
WWE | Wipo information: entry into national phase |
Ref document number: 15505724 Country of ref document: US |
|
ENP | Entry into the national phase in: |
Ref document number: 2017510850 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |